Significant Accounting Policies - License Agreement with Carnegie Mellon University (Details) - USD ($) |
3 Months Ended | ||
|---|---|---|---|
Dec. 17, 2018 |
Dec. 31, 2019 |
Dec. 31, 2018 |
|
| Acquired Finite-Lived Intangible Assets [Line Items] | |||
| Fair value of warrant liability issued | $ 694,134 | $ 0 | |
| Total consideration | 1,227,686 | 4,876 | |
| Research and development | 1,227,686 | 4,876 | |
| License Agreement with Carnegie Mellon University | |||
| Acquired Finite-Lived Intangible Assets [Line Items] | |||
| Cash consideration | 54,000 | ||
| Acquisition costs | 43,463 | ||
| Fair value of common stock | 844,600 | ||
| Fair value of warrant liability issued | 104,902 | ||
| Total consideration | $ 1,046,965 | 1,000,000 | |
| Decrease in intangible assets | 1,500,000 | ||
| Stock Issued During Period, Right to Receive, Shares | 820,000 | ||
| Stock Issued During Period, Shares, Purchase of Assets | 820,000 | ||
| Research and development | $ 1,046,965 | $ 1,000,000 | |
| Fully-diluted common stock held (in percent) | 8.20% | ||
| Funding amount | $ 2,000,000 | ||
| Exercise Price | $ 10.00 | ||
| X | ||||||||||
- Definition It represents the amount of acquisition costs for research and development expense. No definition available.
|
| X | ||||||||||
- Definition It represents the amount of cash consideration for research and development expense in connection with the license agreement. No definition available.
|
| X | ||||||||||
- Definition The value represents decrease in intangible assets. No definition available.
|
| X | ||||||||||
- Definition It represents the amount of fair value of common stock for research and development expense. No definition available.
|
| X | ||||||||||
- Definition The first funding amount. No definition available.
|
| X | ||||||||||
- Definition Percentage of fully diluted common stock held by former stock holders, option holders, warrant holders and note holders of legal entity. No definition available.
|
| X | ||||||||||
- Definition The number of shares to be received as a right pursuant to the Exchange ratio. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. No definition available.
|
| X | ||||||||||
- Details
|